↓ Skip to main content

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III…

Overview of attention for article published in Journal of Clinical Oncology, December 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

news
4 news outlets
policy
2 policy sources
twitter
15 X users
facebook
1 Facebook page

Citations

dimensions_citation
254 Dimensions

Readers on

mendeley
173 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study
Published in
Journal of Clinical Oncology, December 2018
DOI 10.1200/jco.18.01580
Pubmed ID
Authors

Arnon P. Kater, John F. Seymour, Peter Hillmen, Barbara Eichhorst, Anton W. Langerak, Carolyn Owen, Maria Verdugo, Jenny Wu, Elizabeth A. Punnoose, Yanwen Jiang, Jue Wang, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Thomas J. Kipps

X Demographics

X Demographics

The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 173 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 173 100%

Demographic breakdown

Readers by professional status Count As %
Other 31 18%
Researcher 25 14%
Student > Ph. D. Student 15 9%
Student > Master 13 8%
Student > Bachelor 11 6%
Other 30 17%
Unknown 48 28%
Readers by discipline Count As %
Medicine and Dentistry 63 36%
Biochemistry, Genetics and Molecular Biology 21 12%
Pharmacology, Toxicology and Pharmaceutical Science 14 8%
Agricultural and Biological Sciences 5 3%
Nursing and Health Professions 3 2%
Other 15 9%
Unknown 52 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 44. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#937,303
of 25,385,509 outputs
Outputs from Journal of Clinical Oncology
#2,253
of 22,054 outputs
Outputs of similar age
#21,135
of 445,099 outputs
Outputs of similar age from Journal of Clinical Oncology
#43
of 158 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,054 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 445,099 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 158 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.